The most recent World Health Organization (WHO) report reveals a concerning resurgence of tuberculosis, now ranking as a leading infectious disease killer globally. Alarmingly, the Philippines is among the 30 countries with the highest burden of this disease. Approximately 1 million Filipinos have active tuberculosis, causing nearly 70 daily deaths from this curable disease.
One of the key achievements of the 2018 Roadmap towards ending TB in children and adolescents cited during the 2023 United Nations General Assembly High-Level Meeting on the fight against TB is the availability of pediatric formulations for treating drug susceptible TB in children in the form of dispersible fixed-dose combinations (FDCs).
Just recently, the Department of Health National TB Program included the FDC tablets in the program which can simplify and improve treatment for children, providing better adherence and treatment completion.
Faberco Lifesciences Inc. is pleased to announce that we offer the following anti-tuberculosis medications in dispersible tablet form, manufactured by Macleods Pharmaceutical Limited registered in the Philippine FDA: (1) Rifampicin + Isoniazid 75mg/50mg dispersible tablets and (2) Rifampicin + Isoniazid + Pyrazinamide 75mg/50mg/150mg dispersible tablets.
Ending TB requires optimized care and prevention. The most substantial gap in treatment coverage persists among young children and FDCs offer solutions to many of the typical challenges encountered in treating TB in children.